SCHEMBL6803237

SCHEMBL6803237

Cc1ncn(-c2cccc(NC(=O)c3cccc(-c4cccs4)c3)c2)c1C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 5/20 0.44
KIT P10721 4/20 0.44
KCNK3 O14649 1/20 0.44
KCNK9 Q9NPC2 1/20 0.44
HCK P08631 3/20 0.44
NR2C2 P49116 3/20 0.44
BTK Q06187 3/20 0.44
HTR1A P08908 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CCKAR P32238 1/20 0.43
HTR5A P47898 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
EPHA2 P29317 1/20 0.43
POLB P06746 1/20 0.42
GPR142 Q7Z601 2/20 0.42
KAT6A Q92794 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27519956 0.85 HCK (0.48) CSF1RKITKCNK3KCNK9HCK
SCHEMBL6757923 0.78 MEN1 (0.49) CSF1RKITKCNK3KCNK9HCK
SCHEMBL6834840 0.77 FYN (0.51) CSF1RKITKCNK3KCNK9HCK
SCHEMBL7471000 0.74 MEN1 (0.48) CSF1RKITKCNK3KCNK9HCK
SCHEMBL6759881 0.74 EPHA2 (0.49) CSF1RKITKCNK3KCNK9HCK
SCHEMBL6759857 0.73 ABL1 (0.56) KCNK3KCNK9HCKNR2C2BTK
SCHEMBL6756711 0.72 FYN (0.48) CSF1RKITHCKNR2C2BTK
SCHEMBL7118424 0.72 ALDH1A1 (0.58) MEN1KMT2APOLBMAPT
SCHEMBL2337472 0.72 RIPK1 (0.51) MEN1KMT2AMAPT
SCHEMBL7120206 0.69 CYP1A2 (0.51) MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266774-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed
US-6770667-B1 N-((IMIDAZOLYL)-PHENYL)-FLUORENE-1-CARBOXAMIDE DERIVATIVES; 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONISTS; PSYCHOLOGICAL, NERVOUS SYSTEM, EATING, BRAIN AND SLEEP DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266774-A1 Amide compounds TPH1, HTR1A, HTR5A CSF1R 2490/4885KIT 870/4885KCNK3 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.